Latest News and Press Releases

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and...

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences   Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids...

STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

KØBENHAVN, Danmark, 7. april 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 12. marts 2026, hvorunder selskabet vil...

COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares...

Company announcement no. 9 - 2607 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Renovare Therapeutics announces company launch & collaboration with CU Boulder awardee of up to $33.5 million in ARPA-H funding for regenerative therapies